Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
نویسندگان
چکیده
An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients' adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.
منابع مشابه
Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
We reviewed the current information available on nevirapine immediate- and extended-release formulations and its role in single-dose and combination antiretroviral therapy. Nevirapine was approved in 1996 and was the first non-nucleoside reverse-transcriptase inhibitor available for the treatment of HIV-1 infection. Nevirapine has demonstrated good efficacy and a well-characterized safety profi...
متن کاملIntegration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
BACKGROUND Nevirapine is metabolized by CYP2B6 and polymorphisms within the CYP2B6 gene partly explain inter-patient variability in pharmacokinetics. The aim of this study was to model the complex relationship between nevirapine exposure, weight and genetics (based on combined analysis of CYP2B6 516G > T and 983T > C single nucleotide polymorphisms). METHODS Non-linear mixed-effects modelling...
متن کاملEfficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
BACKGROUND This study (VERxVE) compared the efficacy and safety of the new nevirapine extended-release (NVP XR) formulation dosed once daily with NVP immediate release (IR) twice daily in treatment-naive patients. METHODS Randomized, double-blind, double-dummy, parallel group study of HIV-1-infected adult patients with baseline viral load (VL) ≥ 1,000 copies/ml and CD4(+) T-cell count of >50-...
متن کامل48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
Background Wk 24 TRANxITION study data showed patients transitioned from immediate release nevirapine (NVP IR) twice daily (BID) to NVP extended release (NVP XR) once-daily (QD) demonstrated non-inferior efficacy to patients continuing on IR NVP BID [1]. Similar safety was reported for NVP XR and NVP IR in the VERxVE study [2]. Wk 48 efficacy/safety data from TRANxITION study are presented here.
متن کاملEfficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial
BACKGROUND Nevirapine given once-daily for the first 6, 14, or 28 weeks of life to infants exposed to HIV-1 via breastfeeding reduces transmission through this route compared with single-dose nevirapine at birth or neonatally. We aimed to assess incremental safety and efficacy of extension of such prophylaxis to 6 months. METHODS In our phase 3, randomised, double-blind, placebo-controlled HP...
متن کامل